Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 2
1995 1
1996 3
1998 1
1999 4
2001 1
2003 3
2004 1
2005 3
2006 3
2007 1
2008 2
2009 1
2010 1
2011 3
2012 2
2013 1
2014 1
2016 1
2018 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Mecasermin rinfabate.
Kemp SF. Kemp SF. Drugs Today (Barc). 2007 Mar;43(3):149-55. doi: 10.1358/dot.2007.43.3.1079876. Drugs Today (Barc). 2007. PMID: 17380212 Review.
In addition, the serum half-life of unbound rhIGF-I is shorter when administered to patients with growth hormone insensitivity syndrome, who have low serum concentrations of its binding proteins IGFBP-3 and acid-labile subunit, than when administered t …
In addition, the serum half-life of unbound rhIGF-I is shorter when administered to patients with growth hormone insensitiv …
Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment.
Carel JC, Chaussain JL, Chatelain P, Savage MO. Carel JC, et al. Diabetes Metab. 1996 Jul;22(4):251-6. Diabetes Metab. 1996. PMID: 8767171 Review.
Laron syndrome, because of extreme growth deficiency and a lack of alternative treatment, was the first clinical situation in which recombinant human IGF-1 was used. IGF-1 accelerates growth rate in most patients, induces subtle modifications of the craniofacies and decrea …
Laron syndrome, because of extreme growth deficiency and a lack of alternative treatment, was the first clinical situation in which r …
Recombinant IGF-I: Past, present and future.
Bright GM. Bright GM. Growth Horm IGF Res. 2016 Jun;28:62-5. doi: 10.1016/j.ghir.2016.01.002. Epub 2016 Jan 18. Growth Horm IGF Res. 2016. PMID: 26822565 Review.
Investigational agents for the treatment of growth hormone-insensitivity syndrome.
Kemp SF, Thrailkill KM. Kemp SF, et al. Expert Opin Investig Drugs. 2006 Apr;15(4):409-15. doi: 10.1517/13543784.15.4.409. Expert Opin Investig Drugs. 2006. PMID: 16548790 Review.
Growth hormone-insensitivity syndrome (GHIS) is usually caused by mutations in the growth hormone receptor. ...
Growth hormone-insensitivity syndrome (GHIS) is usually caused by mutations in the growth hormone receptor. ...
Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Williams RM, McDonald A, O'Savage M, Dunger DB. Williams RM, et al. Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):311-24. doi: 10.1517/17425255.4.3.311. Expert Opin Drug Metab Toxicol. 2008. PMID: 18363546 Review.
OBJECTIVE: To review the published literature regarding the pharmacokinetics, safety profile and clinical efficacy of Mecasermin rinfabate. METHODS: A comprehensive search via the NCBI PubMed portal was performed using the search terms rhIGF-I/rhIGFBP-3 complex, iPLEX and …
OBJECTIVE: To review the published literature regarding the pharmacokinetics, safety profile and clinical efficacy of Mecasermin rinf …
Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
Ranke MB. Ranke MB. Trends Endocrinol Metab. 2005 May-Jun;16(4):190-7. doi: 10.1016/j.tem.2005.03.011. Trends Endocrinol Metab. 2005. PMID: 15860416 Review.
Insulin-like growth factor I (IGF-I) has many potential therapeutic uses because of its varied effects--growth promotion, insulin-like influence on glucose metabolism, and neuroprotection resulting from cell-proliferative and antiapoptotic properties--but they have not been inves …
Insulin-like growth factor I (IGF-I) has many potential therapeutic uses because of its varied effects--growth promotion, insulin-like influ …
SomatoKine. Insmed.
Norman P. Norman P. Curr Opin Investig Drugs. 2003 Apr;4(4):466-71. Curr Opin Investig Drugs. 2003. PMID: 12808889 Review.
SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potent …
SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtr …
Therapeutic applications of the insulin-like growth factors.
Savage MO, Camacho-Hübner C, Dunger DB. Savage MO, et al. Growth Horm IGF Res. 2004 Aug;14(4):301-8. doi: 10.1016/j.ghir.2004.04.001. Growth Horm IGF Res. 2004. PMID: 15231299 Review.
Several groups of patients have been treated effectively, including individuals with growth hormone insensitivity syndrome (GHIS) secondary to GH receptor deficiency, to IGF-I gene deletion, or to defects in GH signal transduction pathways, patients wi …
Several groups of patients have been treated effectively, including individuals with growth hormone insensitivity sy …
A novel treatment for height growth in patients with growth hormone insensitivity syndrome by cyproheptadine hydrochloride.
Razzaghy-Azar M, Nourbakhsh M, Nourbakhsh M. Razzaghy-Azar M, et al. Clin Endocrinol (Oxf). 2018 Jun;88(6):880-888. doi: 10.1111/cen.13594. Epub 2018 Apr 14. Clin Endocrinol (Oxf). 2018. PMID: 29520979
BACKGROUND: Cyproheptadine HCl (CyproH) is an appetite-stimulating drug and while it was prescribed for a patient with growth hormone insensitivity syndrome (GHIS) for increasing appetite, his height growth was surprisingly increased. ...
BACKGROUND: Cyproheptadine HCl (CyproH) is an appetite-stimulating drug and while it was prescribed for a patient with growth horm …
37 results